tiprankstipranks
Trending News
More News >
Corbion NV (NL:CRBN)
:CRBN
Advertisement

Corbion NV (CRBN) AI Stock Analysis

Compare
2 Followers

Top Page

NL:CRBN

Corbion NV

(LSE:CRBN)

Rating:57Neutral
Price Target:
€17.50
▲(6.71% Upside)
Corbion NV's overall score is driven by strong financial performance with improved profitability despite revenue challenges. The technical analysis suggests bearish momentum, which negatively impacts the score. Valuation metrics indicate a fairly priced stock with a reasonable dividend yield, adding moderate value. The absence of recent significant earnings call details or corporate events leaves the score primarily influenced by financial and technical factors.

Corbion NV (CRBN) vs. iShares MSCI Netherlands ETF (EWN)

Corbion NV Business Overview & Revenue Model

Company DescriptionCorbion N.V. provides lactic acid and lactic acid derivatives, emulsifiers, functional enzyme blends, minerals, vitamins, and algae ingredients worldwide. The company offers ingredient solutions made from renewable resources for the food, home and personal care, pharmaceutical, animal nutrition, medical device, and bioplastics markets. It markets its products through a network of sales offices and distributors. The company was formerly known as CSM N.V. and changed its name to Corbion N.V. in October 2013. Corbion N.V. was founded in 1919 and is headquartered in Amsterdam, the Netherlands.
How the Company Makes MoneyCorbion makes money through the sale of its products across two main business segments: Food and Biochemicals. In the Food segment, it generates revenue by providing food ingredient solutions that enhance the quality, safety, and shelf life of food products. This includes emulsifiers, enzymes, and other food additives. The Biochemicals segment generates revenue through the sale of sustainable biobased chemicals, such as lactic acid and its derivatives, which are used in a wide range of applications, including pharmaceuticals, personal care, and industrial products. Corbion's earnings are further supported by strategic partnerships and collaborations that leverage its expertise in biotechnology to develop innovative solutions for its clients.

Corbion NV Financial Statement Overview

Summary
Corbion NV demonstrates strong profitability with an improved net profit margin of 14.9% and efficient operational management, despite a 10.8% revenue decline. The balance sheet shows moderate leverage with a debt-to-equity ratio of 0.66 and a high return on equity of 24.9%. Cash flow generation has improved, but the conversion from net income remains moderate with a free cash flow to net income ratio of 0.52.
Income Statement
77
Positive
Corbion NV shows a mixed performance in its income statement. The gross profit margin for the latest year is approximately 24.2%, indicating a strong ability to convert revenue into gross profit. However, the net profit margin has improved significantly to approximately 14.9% from the previous year's 5.0%, driven by increased net income. The revenue growth rate shows a decline of 10.8% from the previous year, suggesting challenges in maintaining top-line growth. The EBIT and EBITDA margins are 6.0% and 13.4% respectively, reflecting efficient operational management despite the revenue decline.
Balance Sheet
70
Positive
The balance sheet presents a stable but leveraged financial position. The debt-to-equity ratio is approximately 0.66, indicating moderate leverage. The return on equity stands high at 24.9%, showcasing effective use of shareholders' capital to generate earnings. The equity ratio is 50%, pointing to a well-balanced asset financing structure through equity and liabilities. However, the high debt levels pose a potential risk in a fluctuating market environment.
Cash Flow
65
Positive
The cash flow statement highlights some concerns. The free cash flow growth has been positive, with an increase from €16.1 million to €99.9 million, indicating improved cash generation capability. However, the operating cash flow to net income ratio of 0.96 suggests less cash generation relative to net income, potentially due to working capital needs or other operational factors. The free cash flow to net income ratio stands at 0.52, showing moderate conversion of net income into free cash flow.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.29B1.44B1.46B1.07B986.50M
Gross Profit312.10M352.70M324.30M265.80M269.80M
EBITDA172.00M198.00M194.00M133.10M154.90M
Net Income192.20M72.90M90.00M78.30M73.10M
Balance Sheet
Total Assets1.55B1.70B1.72B1.36B1.09B
Cash, Cash Equivalents and Short-Term Investments49.30M70.20M58.20M42.20M51.60M
Total Debt509.20M785.50M759.20M503.20M335.80M
Total Liabilities773.80M1.06B1.10B806.50M578.20M
Stockholders Equity772.50M636.20M625.70M554.10M516.00M
Cash Flow
Free Cash Flow99.90M16.10M-182.60M-122.00M24.50M
Operating Cash Flow184.10M165.40M53.20M26.70M113.40M
Investing Cash Flow166.00M-146.80M-213.30M-123.70M-81.30M
Financing Cash Flow-371.70M-5.30M173.90M85.90M-23.90M

Corbion NV Technical Analysis

Technical Analysis Sentiment
Negative
Last Price16.40
Price Trends
50DMA
18.73
Negative
100DMA
18.64
Negative
200DMA
20.10
Negative
Market Momentum
MACD
-0.43
Positive
RSI
20.21
Positive
STOCH
9.71
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NL:CRBN, the sentiment is Negative. The current price of 16.4 is below the 20-day moving average (MA) of 18.13, below the 50-day MA of 18.73, and below the 200-day MA of 20.10, indicating a bearish trend. The MACD of -0.43 indicates Positive momentum. The RSI at 20.21 is Positive, neither overbought nor oversold. The STOCH value of 9.71 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NL:CRBN.

Corbion NV Peers Comparison

Overall Rating
UnderperformOutperform
Sector (63)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
63
Neutral
$20.32B12.52-7.33%3.14%2.92%-10.01%
57
Neutral
€948.06M13.958.84%3.90%-3.45%-5.55%
€9.35B22.419.60%
$122.12M-37.84%
€333.82M10.599.81%
€5.67B20.9614.32%
€1.59B59.30
* Consumer Defensive Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
NL:CRBN
Corbion NV
16.40
-4.11
-20.03%
GB:0A00
Akzo Nobel NV
55.82
4.42
8.60%
GB:0RNP
Avantium N.V.
14.44
-9.56
-39.83%
GB:0RHZ
ForFarmers N.V.
4.19
1.48
54.61%
GB:0QVU
IMCD N.V.
96.51
-40.10
-29.35%
GB:0QGH
OCI N.V.
7.53
0.71
10.41%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 01, 2025